Search Results - "Cryer, B"

NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality by Cryer, Byron

“…Although gastrointestinal (GI) morbidity and mortality from NSAIDs continues to be a significant problem, this study by Lanas et al. indicates that the…”
Get full text

Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients by Laine, L., Curtis, S. P., Cryer, B., Kaur, A., Cannon, C. P.

“…Aliment Pharmacol Ther 2010; 32: 1240–1248 Summary Background  Nonsteroidal anti‐inflammatory drugs (NSAID)‐related GI effects vary based on patient…”
Get full text

Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans by Cryer, Byron, Feldman, Mark

“…Background & Aims: The safety of low-dose daily aspirin therapy in the gastrointestinal tract is uncertain. Our objectives were to evaluate the long-term…”
Get full text

The effects of proton pump inhibition on patient‐reported severity of dyspepsia when receiving dual anti‐platelet therapy with clopidogrel and low‐dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial by Vardi, M., Cryer, B. L., Cohen, M., Lanas, A., Schnitzer, T. J., Lapuerta, P., Goldsmith, M. A., Laine, L., Doros, G., Liu, Y., McIntosh, A. I., Cannon, C. P., Bhatt, D. L.

“…Summary Background Dual anti‐platelet therapy with clopidogrel and low‐dose aspirin increases the risk for gastrointestinal clinical events. Omeprazole has…”
Get full text

Risk of Cardiovascular, Gastrointestinal, and renal adverse events associated with Diclofenac immediate and extended release Drug products: an observational study using us claims data by Mladsi, D.M, Goyal, R.K, Cryer, B, Hopkins, W.E, Brater, C.D, Korsnes, J.S, Candrilli, S, Castellsague, J, Varas-Lorenzo, C

Get full text

Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? by Cryer, Byron, Bauer, Douglas C

“…To review and evaluate the evidence regarding possible associations of bisphosphonate use with upper gastrointestinal (GI) tract adverse events (AEs). We…”
Get more information

Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis by Cryer, B., Luo, X., Assaf, A.R., Sands, G., Mardekian, J.

“…Abstract Objective: Gastrointestinal (GI) symptoms are common in patients taking nonselective, nonsteroidal anti-inflammatory drugs (nsNSAIDs) and are often a…”
Get full text

Effects of aging and gastritis on gastric acid and pepsin secretion in humans: A prospective study by Feldman, M, Cryer, B, McArthur, KE, Huet, BA, Lee, E

“…BACKGROUND & AIMS: Recent studies suggesting that gastric secretion does not decrease with aging included few elderly individuals and measured only acid…”
Get full text

The economics of upper gastrointestinal bleeding in a US managed-care setting: a retrospective, claims-based analysis by Cryer, B L, Wilcox, C M, Henk, H J, Zlateva, G, Chen, L, Zarotsky, V

“…To assess 12-month healthcare resource utilization and costs associated with upper gastrointestinal (UGI) bleeding events. Patients hospitalized with a UGI…”
Get more information

Three‐year oral pantoprazole administration is effective for patients with Zollinger–Ellison syndrome and other hypersecretory conditions by METZ, D. C., COMER, G. M., SOFFER, E., FORSMARK, C. E., CRYER, B., CHEY, W., PISEGNA, J. R.

“…Summary Background Zollinger–Ellison syndrome and idiopathic hypersecretion are gastrointestinal hypersecretory conditions requiring long‐term maintenance…”
Get full text

Nonsteroidal anti-inflammatory drug gastrointestinal toxicity by Cryer, Bryron

“…Toxic effects in the upper gastrointestinal tract, primarily complicated gastric and intestinal ulcers, are the most common undesirable effects of the…”
Get full text

NSAID gastrointestinal toxicity by Cryer, Byron

“…Toxic effects in the upper gastrointestinal tract, primarily complicated gastric and intestinal ulcers, are the most common undesirable effects of the…”
Get full text

Disintegration/dissolution profiles of copies of Fosamax (alendronate) by Epstein, S., Cryer, B., Ragi, S., Zanchetta, J. R., Walliser, J., Chow, J., Johnson, M. A., Leyes, A. E.

“…SUMMARY Objective: Poor quality has been reported for some generics and other copies of original products. We performed a pilot study to compare the…”
Get full text

Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non‐steroidal anti‐inflammatory drug use by Cryer, B., Miller, P., Petruschke, R. A., Chen, E., Geba, G. P., Papp, A. E.

“…Summary Background : Both oral bisphosphonates and non‐steroidal anti‐inflammatory drugs have the potential to irritate the upper gastrointestinal mucosa, and…”
Get full text

COX-1–Sparing NSAIDs—Is the Enthusiasm Justified? by Peterson, Walter L, Cryer, Byron

“…An editorial addresses two articles that are among the first published peer-reviewed multicenter studies of COX-1-sparing NSAIDs. Details of the studies, by…”
Get full text

Effect of cyclooxygenase‐2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention by Scheiman, J. M., Greenson, J. K., Lee, J., Cryer, B.

“…Summary Cyclooxygenase (COX)‐2 expression and prostaglandin production is increased by Helicobacter pylori infection. Non‐selective COX inhibitors reduce…”
Get full text

A Randomized Study of Lubiprostone for Opioid‐Induced Constipation in Patients with Chronic Noncancer Pain by Cryer, Byron, Katz, Seymour, Vallejo, Ricardo, Popescu, Anca, Ueno, Ryuji

“…Objective To evaluate the efficacy and safety of oral lubiprostone for relieving symptoms of opioid‐induced constipation (OIC) in patients with chronic…”
Get full text

Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies by Goldstein, Jay L, Cryer, Byron

“…Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective anti-inflammatory and analgesic agents and are among the most commonly used classes of medications…”
Get full text

Reducing the Risks of Gastrointestinal Bleeding with Antiplatelet Therapies by Cryer, Byron

“…In the treatment of cardiovascular disease, clinicians commonly are caught between the competing considerations of cardiovascular benefit and gastrointestinal…”
Get full text

The AGA Equity Project: Where We Are, and Where We Go From Here by Quezada, Sandra M, Carethers, John M, Abreu, Maria, Hendersen, Wendy, Omary, M Bishr, Cryer, Byron

Get full text